Home
Biorecognition

News archive for Biorecognition

Together with Nathalie Reuter and Bengt-Erik Haug from the Chemistry Department and Alexander Lundervold from the Høgskulen på Vestlandet (HVL) we got funding for the project «Towards better computational approaches and responsible innovation strategies in early drug discovery: application to antibiotics and COPD» under the Centre for Digital Life umbrella. In this project, we are aiming toward... Read more
Our EXPLORE network application aiming at targeting the TPP riboswitch for hit discovery for new antibiotics will receive funding from JPI-AMR! Other partners in the network are Daniel Lafontaine (Université de Sherbrooke, Canada), Matthias Mack (Mannheim University of Applied Sciences, Germany), Petr Bartunek (CZ-OPENSCREEN, Czech Republic), Bengt Erik Haug (University of Bergen Norway) and... Read more
Researcher's Grand Prix-cadidate Illimar Hugo Rekand is working to keep us healthy. He is investigating new opportunities for making new medicines in a world where antibiotic resistance is an increasing challenge.
About state-of the art of riboswitch ligand design and future perspectives.
Sarsia Seed recently announced their new seed funds in Bergen consisting of 300 million NOK. Initial investment can be in the biotechnology company Pluvia founded by Prof. Aurora Martinez according to Sarsia officials.
PhD-candidate Oscar Aubi Catevilla will defend his thesis: “Discovery of small-molecule activity modulators of bacterial and human phenylalanine hydroxylase”
The Brenk lab will receive funding from NFR for developing future antibiotics acting via riboswitch binding. This project will fund two postdoc positions for three years, one in the lab of Bengt Erik Haug (Department of Chemistry) and one in the Brenk group. We are looking forward to continuing an exiting research project!
Auroras work at USC highlighted in the J1 Newsletter.
Biorecognition won the Faculty of Medicine and Dentistry prize for best research group.
In 2014 Ruth was awared nearly 60,000 Euros over two years from the Gutenberg Lehrkolleg for research oriented teaching.
To Hit or Not to Hit, That Is the Question – Genome-wide Structure-Based Druggability Predictions for Pseudomonas aeruginosa Proteins
The Biorecognition group at the Department of Biomedicine represents one of the four nodes in the new NOR-Openscreen infrastructure. The infrastructure will support the discovery of biologically active substances in all areas of the Life Sciences by providing transnational, open access to the most advanced technologies, chemical and biological resources as well as expertise through Europe.
PhD candidate Helene J. Bustad from Biorecognition won the poster prize at this year's NBS Contact Meeting at Røros.
The Research Council of Norway will fund 16 new research infrastructures. One of them is the Norwegian NMR Platform, which has been awarded 51.4 MNOK for new NMR equipment.

Pages